Veracyte (VCYT) Q2 2026 earnings review
Milestone Launches Meet Margin Expansion
Veracyte delivered a stellar Q2, launching two major products (Prosigna LDT and TrueMRD) while simultaneously crushing profitability metrics. Total revenue grew 15% YoY to $150.3M, fueled by relentless momentum in Decipher and Afirma testing volumes. Unlike many diagnostics companies that burn cash to scale, Veracyte generated $45.8M in operating cash flow this quarter and achieved a massive 29.2% Adjusted EBITDA margin. Management confidently raised FY26 revenue guidance to $590-$596M, validating the durability of their core testing engine.
🐂 Bull Case
Decipher and Afirma are generating highly predictable, double-digit growth. Testing revenue jumped 19% YoY, driven by 29,700 Decipher tests (+17%) and 18,600 Afirma tests (+10%).
Non-GAAP gross margin expanded to 75% (up from 72% a year ago). The company is funding its massive R&D pipeline entirely through internally generated cash flow.
🐻 Bear Case
GAAP R&D expenses spiked 81% YoY to $29.4 million. Developing the clinical evidence required to commercialize Prosigna and TrueMRD is expensive and introduces execution risk.
Biopharmaceutical and other revenue fell to just $0.8 million (down from $4.3M in 25Q2) due to the liquidation of Veracyte SAS. The company is now entirely dependent on pure testing volume.
⚖️ Verdict: 🟢
Bullish. It is rare to see a diagnostics company successfully launch two major product lines in a single quarter while expanding gross margins to 75% and generating over $45M in cash. Veracyte is a well-oiled machine.
Key Themes
Decipher Market Penetration Accelerating
Decipher Prostate remains the company's undeniable growth engine. Volume reached approximately 29,700 tests in Q2, representing 17% YoY growth. This translates to $91.9 million in revenue (+20% YoY), showcasing that strong pricing power and positive volume mix are compounding. The test is becoming an entrenched standard of care in urology.
TrueMRD Launch with Immediate Medicare Coverage
Veracyte successfully executed the commercial launch of TrueMRD for muscle-invasive bladder cancer (MIBC). Crucially, they secured Medicare coverage right out of the gate—a significant regulatory and macro win for a novel, whole-genome sequencing-based monitoring platform. This removes a massive commercial bottleneck.
Afirma's Operational Renaissance Continues
Afirma delivered 10% volume growth (18,600 tests) and 18% revenue growth ($51.2 million). This outsized revenue growth relative to volume demonstrates the ongoing financial benefit of the V2 transcriptome workflow transition, which reduced the test's 'no-result rate' and directly padded the bottom line.
The Hidden Cost of Innovation: R&D Spend Spike
While management rightfully champions a 29.2% Adjusted EBITDA margin, looking under the hood reveals a contradiction to the pure efficiency narrative: GAAP Research and Development expenses skyrocketed 81% YoY to $29.4 million. The heavy lift required for clinical trials (like OPTIMA) and pipeline expansions is eating heavily into operating profits before adjustments.
Prosigna LDT Launch Carries High Evidence Burden
The Prosigna Breast Test was officially launched in the U.S. for early-stage HR+ breast cancer. However, commercial success against deeply entrenched incumbents (like Oncotype) hinges almost entirely on securing Level 1A evidence from the OPTIMA trial to guarantee NCCN guideline inclusion. Without this, the launch will stall.
Digital Pathology Competitors Circling
Emerging low-cost AI and digital pathology (DPAI) startups continue to target the prostate space. While Veracyte leans heavily on its clinical 'evidence moat' (nearly 60 abstracts in Q2 alone) to defend Decipher's 65%+ market share, any technological leap by AI competitors could eventually pressure Veracyte's $2,900+ average selling prices.
Macro Resilience in Reimbursement
Securing Medicare coverage for TrueMRD represents a significant macro victory. The regulatory and reimbursement environment for molecular diagnostics has tightened considerably. Gaining immediate coverage for a whole-genome sequencing application proves Veracyte's 'evidence-first' strategy resonates with payers.
Other KPIs
Accelerating. Cash flow from operations for the first six months of 2026 reached $81.0 million, more than double the $38.9 million generated in the same period in 2025. This exceptional cash conversion fully funds the aggressive R&D pipeline without diluting shareholders.
Accelerating. Up from 72% in Q2 2025. The 300 basis point expansion highlights incredible operating leverage. As testing volumes for Decipher and Afirma scale, unit economics are continuously improving, shielding the company from broader inflationary pressures.
Guidance
Accelerating. Raised from the previous range of $582 - $592 million. The new midpoint ($593M) implies 14.5% YoY growth over FY25's ~$517M. This raise reflects absolute confidence in the core testing business, as it explicitly excludes contributions from the newly launched Prosigna and TrueMRD tests.
Accelerating. Raised from the prior $570 - $580 million range. Represents aggressive 17% to 18% YoY growth. The core Decipher and Afirma tests are carrying the entire weight of this guidance increase.
Stable. The company reiterated its guidance to exceed a 26% margin for the full year. Given they achieved 30.8% in Q1 and 29.2% in Q2, the second half of the year implies heavy commercial investments and SG&A ramp-up to support the Prosigna and TrueMRD launches.
Key Questions
Prosigna Commercial Ramp
With Prosigna LDT now launched, what are the leading indicators we should monitor for commercial traction prior to potential NCCN guideline inclusion?
R&D Spend Trajectory
R&D expenses spiked dramatically to $29.4M this quarter. Should we view this as a new normalized run-rate to support TrueMRD indication expansions, or a temporary peak tied to OPTIMA and initial launch activities?
TrueMRD Adoption Curve
Now that TrueMRD has secured Medicare coverage for MIBC, how rapidly do you expect the existing Decipher urology sales channel to drive cross-selling and adoption in the second half of the year?